New Stock Activities - Companies currently in the IPO process include Botai Cheliang, Xipuni, and Zijin Gold International [1] - Chery Automobile is at the pricing stage, while Different Group is set for its listing date [1] Earnings Announcements - JBB Builders and Chuangneng Group are scheduled to announce their earnings [1] Shareholder Meetings - Companies holding shareholder meetings include Xinhua Wencuan, Jiajin Investment International, and Everbright Securities [1] - Other companies with scheduled meetings are Jiajin Investment International, Huangdafukong, Liangqing Holdings, Youran Muye, and Jinshi Holdings Group [1] Trading Suspension and Resumption - Changhong Jiahua is set to resume trading [1] Dividend Distribution - Companies with upcoming dividend-related dates include Tian Ge Interactive (ex-dividend date), KLN (dividend payment date), COSCO Shipping Holdings (ex-dividend date), Anta Sports (dividend payment date), and Yisheng Biotechnology (dividend payment date) [1] - Other companies with dividend-related dates include Tai Hing Group (ex-dividend date), Longji Group (dividend payment date), Zhou Li Fu (ex-dividend date), and Junjie Group Holdings (ex-dividend date) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） – 1 – 除上文所述者外，認購協議A（經補充協議A及日期為二零二五年八月五日及二 零二五年八月二十六日的延長函件修訂及補充）的所有其他條款及條件將維持 不變，且繼續全面有效及生效。 認購協議B 根據認購協議B（經補充協議B及日期為二零二五年八月五日及二零二五年八月 二十六日的延長函件修訂及補充），倘先決條件未能於二零二五年九月十六日 或認購人B與本公司可能書面協定的其他日期及時間前達成，則認購人B與本 公司於認購協議B（經補充協議B及日期為二零二五年八月五日及二零二五年八 月二十六日的延長函件修訂及補充）項下的所有權利、義務及責任將予停止及 終止，任何一方均不得向另一方提出任何申索，惟先前違反有關條款者則除外。 由於需要額外時間達成認購協 ...

领航医药生物科技(0399.HK)今日早盘一度大跌22.12%至0.405港元，股价创7月21日以来近2个月新低。 领航医药生物科技昨日晚间公告，内容有关公司与中国北方证券集团有限公司(作为配售代理)所订立日期为2025年8月21日的配售协议，以按配售价每股配 售股份0.415港元认购最多1.45亿股公司配售股份。董事会宣布，由于配售协议所载的先决条件未能于2025年9月11日或之前达成，配售协议已失效且配售事 项将不会进行。 据悉，领航医药生物科技今年8月21日曾公告，拟发行1.45亿股配售股份净筹5882.5万港元。公司拟将配售事项所得款项净额全数用作集团的于发展区块链技 术业务资金。公告发布翌日(8月22日)，该股大幅收涨10.87%。(格隆汇) ...

2025年9月9日已获百慕大注册署批准，将领航医药生物科技有限公司改名为：Starcoin Group, Ltd.(星太 链集团有限公司)。 ...

Core Viewpoint - The stock of Pioneer Pharma Biotechnology (00399) has dropped over 19% following the announcement that its placement agreement for up to 145 million new shares, aimed at raising HKD 60.18 million, has lapsed due to unmet conditions by September 11 [1] Group 1: Company Announcement - Pioneer Pharma announced that the placement agreement has become invalid, but the board believes this will not have a significant adverse impact on the company's current operations and financial status [1] - On August 21, the company had previously announced a plan to place shares at HKD 0.415 each, aiming to raise approximately HKD 58.83 million, which was intended for funding the development of blockchain technology [1] Group 2: Market Reaction - As of the report, Pioneer Pharma's stock price fell by 19.23%, trading at HKD 0.42, with a trading volume of HKD 16.28 million [1]

Core Viewpoint - The stock of Pioneer Pharma Biotechnology (00399) has dropped over 19% following the expiration of a share placement agreement aimed at raising HKD 60.18 million, which failed to meet its conditions by the deadline of September 11 [1] Group 1: Stock Performance - As of the report, Pioneer Pharma's stock is down 19.23%, trading at HKD 0.42, with a trading volume of HKD 16.28 million [1] Group 2: Share Placement Agreement - The company announced that the share placement agreement for a maximum of 145 million new shares has become invalid due to unmet conditions [1] - The board believes that the failure of the placement agreement will not have any significant adverse impact on the company's current operations and financial status [1] Group 3: Previous Announcements - On August 21, the company had previously announced a plan to place shares at HKD 0.415 each, aiming to raise approximately HKD 58.83 million, which was intended for funding the development of blockchain technology [1]

Group 1 - The company, Pioneer Pharma Biotech (00399), announced a share placement at a price of HKD 0.415 per share, with a maximum of 145 million shares to be placed [1] - The placement agreement has become invalid as the conditions precedent were not met by September 11, 2025, and the placement will not proceed [1] - All responsibilities under the placement agreement between the placement agent and the company will terminate, and no claims can be made by either party regarding the placement agreement [1]

Group 1 - The company announced that the previously planned placement of up to 145 million shares at HKD 0.415 per share has become invalid [1] - The reason for the invalidation is that the conditions precedent of the agreement were not met by September 11, 2025 [1] - As a result, the placement will not proceed, and both the placement agent and the company have terminated their responsibilities under the agreement, with no claims allowed between the parties [1]

格隆汇9月11日丨领航医药生物科技(00399.HK)公告，内容有关公司与中国北方证券集团有限公司（作 为配售代理）所订立日期为2025年8月21日的配售协议，以按配售价每股配售股份0.415港元认购最多 1.45亿股公司配售股份。董事会宣布，由于配售协议所载的先决条件未能于2025年9月11日或之前达 成，配售协议已失效且配售事项将不会进行。 ...

领航医药生物科技(00399)公布，就按配售价每股配售股份0.415港元配售最多1.45亿股公司配售股份， 由于配售协议所载的先决条件未能于2025年9月11日或之前达成，配售协议已失效且配售事项将不会进 行。配售代理及公司于配售协议项下的所有责任将告终止及终结，且任何订约方概不得就配售协议向另 一方提出任何申索。 ...